In March 2019 researchers from Australia and UCL Institute of Child Health in London, UK published the results of their study to assess whether the genetic score for caffeine metabolism (presence of the CYP1A2 genotype which makes individuals less effective at metabolizing caffeine) altered the association between coffee consumption and the risk of cardiovascular disease. A total of 347,077 individuals from the UK including 8,368 with cardiovascular disease, for whom genetic data and information on coffee consumption was available, were included in the study. Results showed that compared with drinking 1-2 cups/day, the risk of cardiovascular disease was increased by 11% for non-drinkers, 7% for drinkers of decaffeinated coffee, and 22% for those who reported drinking 6+ cups/day. There did not appear to be any association between the CYP1A2 genotype and genetic score for caffeine and the risk of cardiovascular disease.
Zhou A, Hyppönen E. Long-term coffee consumption, caffeine metabolism genetics, and risk of cardiovascular disease: a prospective analysis of up to 347,077 individuals and 8368 cases. Am J Clin Nutr. 2019 Mar 1;109(3):509-516